Abstract

Metastasis via lymphatic vessels or blood vessels is the leading cause of death for breast cancer, and lymphangiogenesis and angiogenesis are critical prerequisites for the tumor invasion–metastasis cascade. The research progress for tumor lymphangiogenesis has tended to lag behind that for angiogenesis due to the lack of specific markers. With the discovery of lymphatic endothelial cell (LEC) markers, growing evidence demonstrates that the LEC plays an active role in lymphatic formation and remodeling, tumor cell growth, invasion and intravasation, tumor–microenvironment remodeling, and antitumor immunity. However, some studies have drawn controversial conclusions due to the variation in the LEC markers and lymphangiogenesis assessments used. In this study, we review recent findings on tumor lymphangiogenesis, the most commonly used LEC markers, and parameters for lymphangiogenesis assessments, such as the lymphatic vessel density and lymphatic vessel invasion in human breast cancer. An in-depth understanding of tumor lymphangiogenesis and LEC markers can help to illustrate the mechanisms and distinct roles of lymphangiogenesis in breast cancer progression, which will help in exploring novel potential predictive biomarkers and therapeutic targets for breast cancer.

Highlights

  • The latest data show that breast cancer has become the most common malignant carcinoma, with 2.26 million new cases in 2020 worldwide [1]

  • We summarized recent findings on tumor lymphangiogenesis, the most commonly used lymphatic endothelial cell (LEC) markers, and parameters for lymphangiogenesis assessment, such as the lymphatic vessel density (LVD) and lymphatic vessel invasion (LVI) in human breast cancer

  • D2-40, lymphatic vessel endothelial hyaluronan receptor-1 (LYVE-1), and prospero homeobox gene protein 1 (PROX-1) are recognized LEC markers in human breast cancer, among which D2-40 has the best performance in lymphangiogenesis assessment from the current study

Read more

Summary

Introduction

The latest data show that breast cancer has become the most common malignant carcinoma, with 2.26 million new cases in 2020 worldwide [1]. Metastasis via lymphatic vessels or blood vessels is the leading cause of death for breast cancer, and tumor lymphangiogenesis and angiogenesis are critical prerequisites for the tumor invasion–metastasis cascade [2,3,4]. Ginter et al [19], found that lymphatic vessels were occasionally present in tumor cell nests or tumor-associated stroma and did not participate in metastasis. These discrepant findings may be partly attributable to the difference in the lymphatic markers and stains used, inconsistent counting methods for LVD, and the distinct subpopulations of patients across studies. A profound understanding of tumor lymphangiogenesis and LEC markers could help to delineate the mechanisms and distinct roles of lymphangiogenesis in breast cancer progression, facilitating the exploration of novel potential predictive biomarkers and therapeutic targets for breast cancer

Tumor Lymphangiogenesis
Lymphatic Capillaries and Collecting Lymphatics
Tumor Lymphangiogenesis and Lymphatic Endothelial Cellular Origins
Markers of LECs or Lymphatic Vessels
Morphology of Tumor-Associated Lymphatic Vessels
Evaluation
Lymphangiogenesis in the Era of Precision Medicine
Conclusions
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call